Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study
For patients with T1cN0M0-stage HER2+ breast cancer, NAT demonstrated comparable OS and BCSS to AT. Patients who achieved pCR after NAT exhibited significantly better survival outcomes compared with those who received AT.
Authors
- Anbang Hu (ORCID: https://orcid.org/0000-0003-0432-8081)
- Yuhang Shang
- Mingcui Li (ORCID: https://orcid.org/0000-0002-9413-7723)
- Zhiyuan Rong
- Yunqiang Duan (ORCID: https://orcid.org/0000-0003-0143-9368)
- Jiayang Zhang
- Zhengbo Fang
- Yanling Li (ORCID: https://orcid.org/0009-0006-2328-3666)
- Jiarui Zhang (ORCID: https://orcid.org/0000-0003-4776-852X)
- Xuelian Wang (ORCID: https://orcid.org/0000-0002-5073-1827)
- Jiangwei Liu (ORCID: https://orcid.org/0000-0002-7652-9379)
- Baoliang Guo (ORCID: https://orcid.org/0000-0002-4022-6739)
- Yansong Liu (ORCID: https://orcid.org/0000-0002-9618-5243)
- Weilun Cheng (ORCID: https://orcid.org/0000-0001-5968-509X)
- Fanjing Kong (ORCID: https://orcid.org/0000-0003-4305-8264)
- S. Shakila
- Hanyu Zhang (ORCID: https://orcid.org/0000-0003-2259-1721)
Institutions
- Harbin Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2024-09-22
- DOI
- https://doi.org/10.1002/cncr.35581
- Citations
- 4
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- National Natural Science Foundation of China
- National Cancer Institute